NEW USING (R)-(-)-2-[5-(4-FLUOROPHENYL)-3-PYRIDYLMETHYLAMINOMETHYL]-CHROMAN AND ITS PHYSIOLOGICALLY ACCEPTABLE SALTS Russian patent published in 2006 - IPC A61K31/4433 A61P25/14 A61P25/16 

FIELD: medicine.

SUBSTANCE: invention proposes a medicinal preparation for treatment of extrapyramidal disorders (Parkinson's disease, dyskinetic and choreic syndromes, in particular, Huntington chorea, dystonic syndromes, later dyskinesia, tremor, Gilles de la Tourette's disease, ballism, fatigue legs syndrome and Wilson's disease), and a pharmaceutical composition and a set for the same designation also. As a medicinal preparation invention proposes (R)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chroman or its physiologically acceptable salt known early as a combined selective antagonist of dopamine D₂ receptors and antagonist of serotonin receptor of 1A subtype. These properties and high affinity to D₃ receptor show favorable effect on extrapyramidal and motor systems. Pharmaceutical composition and set comprise (R)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chroman or its salt and a medicinal preparation against Parkinson's disease as active compounds. The compound (R)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chroman decreased extrapyramidal moving disorders caused by neuroleptics and enhanced their anti-parkinsonic effect, i. e. it shows property to diminish symptoms of Parkinson's disease and to enhance the general activity.

EFFECT: improved and valuable medicinal properties of compound and pharmaceutical composition.

26 cl, 10 ex